Patents by Inventor Lida WU

Lida WU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12612600
    Abstract: A method for preparing mesenchymal stem cells (MSCs) is provided. The method includes providing expanded potential stem cells or a first cell culture including the expanded potential stem cells; culturing the expanded potential stem cells or the first cell culture in a trophoblast stem cell (TSC) differentiation medium to obtain trophoblast stem cells or a second cell culture including the trophoblast stem cells; culturing the trophoblast stem cells or the second cell culture in a mesenchymal stem cell (MSC) differentiation medium to obtain mesenchymal stem cells or a third cell culture including the mesenchymal stem cells; and passaging the mesenchymal stem cells or the third cell culture in an MSC expansion medium while maintaining characteristics of the mesenchymal stem cells.
    Type: Grant
    Filed: March 28, 2025
    Date of Patent: April 28, 2026
    Assignee: ALLIFE MEDICINE (BEIJING) LIMITED
    Inventors: Shixin Gong, Yuchun Gu, Nan Li, Qinqing Peng, Lida Wu
  • Patent number: 12600954
    Abstract: A method for preparing hematopoietic endothelial cells and a method for preparing hematopoietic stem cells are provided, comprising inducing hematopoietic mesodermal cells to express transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG at specific time periods during the conversion of induced pluripotent stem cells into the hematopoietic endothelial cells or the hematopoietic stem cells. The method can increase the preparation efficiency of at least one of the hematopoietic endothelial cells and the hematopoietic stem cells (including long-term hematopoietic stem cells).
    Type: Grant
    Filed: March 19, 2025
    Date of Patent: April 14, 2026
    Assignee: ALLIFE MEDICINE (BEIJING) LIMITED
    Inventors: Rulong Du, Lei Yu, Wenjing Huang, Xuening Wu, Yuchun Gu, Lida Wu
  • Patent number: 12545898
    Abstract: Disclosed is an efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and a use. The platform can efficiently perform reprogramming, and only requires the use of a minimal number of reprogramming factors (OCT4, SOX2, E6, E7). During the single clone separation stage of the present invention, SSEA4/TRA-1-60 is used as a screening marker, and a large number of single cell clones are obtained by means of flow cytometry. The platform described in the present invention has advantages such as high reprogramming efficiency, high safety, easy operation, and large-scale production.
    Type: Grant
    Filed: November 17, 2023
    Date of Patent: February 10, 2026
    Assignee: ALLIFE MEDICINE (ZHUHAI) LIMITED
    Inventors: Lida Wu, Yuchun Gu
  • Publication number: 20250281669
    Abstract: Provided is a method for preparing a skull flap by photo-curing 3D (three dimensions) printing, including the following steps: (1) constructing a 3D printing model: generating a corresponding 3D model based on a cranial scan data of a patient; (2) preparing a 3D printing ink: weighing a photo-crosslinking hydrogel, mixing the photo-crosslinking hydrogel and a nanoclay solution to obtain a mixed system, and then adding a photoinitiator and a photoresist into the mixed system to obtain the 3D printing ink; and (3) conducting photo-curing 3D printing: subjecting the 3D printing ink to ultrasonic mixing, then filling into an ink tank of a photo-curing 3D printer, transferring the corresponding 3D model into the photo-curing 3D printer, and subjecting the corresponding 3D model to printing to obtain the skull flap; wherein the nanoclay solution comprises an extracellular matrix component.
    Type: Application
    Filed: August 21, 2024
    Publication date: September 11, 2025
    Inventors: Yilong WANG, Yuchun GU, Weiqi CHEN, Bowen CHI, Lida WU, Yongjun WANG, Lingling JIANG
  • Publication number: 20250281670
    Abstract: Provided is a three dimensional (3D) printing photo-curing composition suitable for skull repair. The 3D printing photo-curing composition suitable for skull repair includes the following components: nanoclay; a photo-crosslinking hydrogel; at least one photoinitiator; and at least one photoresist.
    Type: Application
    Filed: October 15, 2024
    Publication date: September 11, 2025
    Inventors: Yilong WANG, Yuchun GU, Weiqi CHEN, Bowen CHI, Lida WU, Yongjun WANG, Lingling JIANG
  • Patent number: 12398370
    Abstract: A medium combination and a method for inducing iPSC differentiation to obtain macrophages and use thereof are provided. The medium combination includes a first stage medium to a sixth stage medium. The first stage medium is an E8 complete medium containing a ROCK pathway inhibitor and polyvinyl alcohol, the second stage medium is an E8 complete medium containing a GSK-3? inhibitor, the third stage medium includes an M1 medium and an M2 medium, the fourth stage medium is an M3 medium, the fifth stage medium is an M4 medium, and the sixth stage medium is an M5 medium.
    Type: Grant
    Filed: February 14, 2025
    Date of Patent: August 26, 2025
    Assignee: ALLIFE MEDICINE (BEIJING) LIMITED
    Inventors: Shixin Gong, Yuchun Gu, Nan Li, Qinqing Peng, Lida Wu
  • Publication number: 20250250543
    Abstract: A method for preparing mesenchymal stem cells (MSCs) is provided. The method includes providing expanded potential stem cells or a first cell culture including the expanded potential stem cells; culturing the expanded potential stem cells or the first cell culture in a trophoblast stem cell (TSC) differentiation medium to obtain trophoblast stem cells or a second cell culture including the trophoblast stem cells; culturing the trophoblast stem cells or the second cell culture in a mesenchymal stem cell (MSC) differentiation medium to obtain mesenchymal stem cells or a third cell culture including the mesenchymal stem cells; and passaging the mesenchymal stem cells or the third cell culture in an MSC expansion medium while maintaining characteristics of the mesenchymal stem cells.
    Type: Application
    Filed: March 28, 2025
    Publication date: August 7, 2025
    Applicant: ALLIFE MEDICINE (BEIJING) LIMITED
    Inventors: Shixin GONG, Yuchun GU, Nan LI, Qinqing PENG, Lida WU
  • Publication number: 20250250544
    Abstract: A method for preparing hematopoietic endothelial cells and a method for preparing hematopoietic stem cells are provided, comprising inducing hematopoietic mesodermal cells to express transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG at specific time periods during the conversion of induced pluripotent stem cells into the hematopoietic endothelial cells or the hematopoietic stem cells. The method can increase the preparation efficiency of at least one of the hematopoietic endothelial cells and the hematopoietic stem cells (including long-term hematopoietic stem cells).
    Type: Application
    Filed: March 19, 2025
    Publication date: August 7, 2025
    Applicant: ALLIFE MEDICINE (BEIJING) LIMITED
    Inventors: Rulong DU, Lei YU, Wenjing HUANG, Xuening WU, Yuchun GU, Lida WU
  • Publication number: 20250179434
    Abstract: A medium combination and a method for inducing iPSC differentiation to obtain macrophages and use thereof are provided. The medium combination includes a first stage medium to a sixth stage medium. The first stage medium is an E8 complete medium containing a ROCK pathway inhibitor and polyvinyl alcohol, the second stage medium is an E8 complete medium containing a GSK-3? inhibitor, the third stage medium includes an M1 medium and an M2 medium, the fourth stage medium is an M3 medium, the fifth stage medium is an M4 medium, and the sixth stage medium is an M5 medium.
    Type: Application
    Filed: February 14, 2025
    Publication date: June 5, 2025
    Applicant: ALLIFE MEDICINE (BEIJING) LIMITED
    Inventors: Shixin GONG, Yuchun GU, Nan LI, Qinqing PENG, Lida WU
  • Publication number: 20250049847
    Abstract: The present invention discloses a method and its application for inducing iPSC differentiation to obtain CD34+cells and NK cells. The method utilizes the three-dimensional structure of the embryoid bodies to provide a favorable differentiation microenvironment for iPSC differentiation, and can start producing a high proportion of CD34+cells on the 4th day under hypoxic induction culture conditions. Subsequently, the production of iPSC induced NK cell differentiation is significantly increased by adhering to the embryoid bodies wall or digesting and resuspension induction, And the induced differentiation of NK cells can exert a killing effect on tumor cells in a short period of time, with strong tumor killing ability, suitable for the production and clinical application of large-scale cell preparations.
    Type: Application
    Filed: August 3, 2022
    Publication date: February 13, 2025
    Applicant: ALLIFE MEDICINE (BEIJING) LIMITED
    Inventors: Shixin GONG, Yuchun GU, Nan LI, Mingyue JIANG, Wenhua CAO, Qinqing PENG, Lida WU
  • Publication number: 20240252687
    Abstract: The present invention relates to gene therapy for wet age-related macular degeneration using iPSC-derived cells as vectors. CRISPR technology is used to perform site-directed dual gene editing of iPSCs, neurotrophic factors CNTF and miR-126 are expressed at the same time, and gene-edited IPSCs are then induced to differentiate into RPE cells. The RPE cells obtained by the induced differentiation can repair damaged RPE cells on CNV and inhibit the generation of choroidal neovascularization. In addition, the RPE cells can express the neurotrophic factors CNTF and miR-126 to fundamentally treat wet age-related macular degeneration, which has very good clinical application prospects.
    Type: Application
    Filed: February 5, 2024
    Publication date: August 1, 2024
    Applicant: Allife Medicine (Zhuhai) Limited
    Inventors: Lida WU, Yuchun Gu
  • Publication number: 20240247230
    Abstract: Provided are a genetically modified oligodendrocyte progenitor cell, a preparation method therefor and a use thereof. Also provided is a method capable of simultaneously repairing myelin, promoting myelin production, and reducing inflammatory responses and autoimmune damage; the method comprises a genetically engineered oligodendrocyte progenitor cell achieving direct repair of a myelin sheath by means of transplantation of the genetically modified oligodendrocyte progenitor cell, which can alleviate an inflammatory response of the nerve and improve nerve function. This has very good application prospects in the clinical treatment of multiple sclerosis.
    Type: Application
    Filed: February 29, 2024
    Publication date: July 25, 2024
    Inventors: Yuchun GU, Lida WU
  • Publication number: 20240240141
    Abstract: A rapid and efficient clinical grade pigment epithelium induction method, a kit, and an application. Provided is a method for rapidly and efficiently inducing retinal pigment epithelium (RPE). IPSCs are directionally induced in three stages, such that an RPE generation duration can be greatly shortened. Specifically, the method comprises using a culture medium containing a small molecule compound for cell culture, the small molecule compound comprising a BMP signaling pathway inhibitor, a Wnt pathway inhibitor, inhibitors for TGF-BI receptors ALK5, ALK4 and ALK7, a ROCK pathway inhibitor, a WNT signaling pathway activator, a VEGFR kinase inhibitor, a GSK signaling pathway inhibitor, a VEGFR kinase inhibitor, vitamins, and the like.
    Type: Application
    Filed: February 5, 2024
    Publication date: July 18, 2024
    Applicant: ALLIFE MEDICINE (ZHUHAI) LIMITED
    Inventors: Lida WU, Yuchun Gu
  • Publication number: 20240207316
    Abstract: The present invention belongs to the field of biological medicines, and particularly relates to a chimeric receptor for improving the killing activity of immune cells and an application thereof. Specifically, the present invention provides a fusion protein. The fusion protein comprises an extracellular part, an extracellular hinge region, a transmembrane region, and an intracellular region. Most preferably, the amino acid sequence of the fusion protein of the present invention is formed by sequentially connecting SEQ ID NO.: 1, SEQ ID NO.: 3, SEQ ID NO.: 5, SEQ ID NO.: 7, SEQ ID NO.: 9 and SEQ ID NO.: 11, and the immune cells expressing the fusion protein have strong killing activity.
    Type: Application
    Filed: November 21, 2023
    Publication date: June 27, 2024
    Applicant: ALLIFE MEDICINE (BEIJING) LIMITED
    Inventors: Lida WU, Yuchun GU
  • Publication number: 20240191205
    Abstract: Disclosed is an efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and a use. The platform can efficiently perform reprogramming, and only requires the use of a minimal number of reprogramming factors (OCT4, SOX2, E6, E7). During the single clone separation stage of the present invention, SSEA4/TRA-1-60 is used as a screening marker, and a large number of single cell clones are obtained by means of flow cytometry. The platform described in the present invention has advantages such as high reprogramming efficiency, high safety, easy operation, and large-scale production.
    Type: Application
    Filed: November 17, 2023
    Publication date: June 13, 2024
    Applicant: ALLIFE MEDICINE (ZHUHAI) LIMITED
    Inventors: Lida WU, Yuchun GU
  • Publication number: 20240093148
    Abstract: Provided are a method for differentiating human induced pluripotent stem cells into oligodendrocytes, and a kit and the use. The method comprises culturing stem cells by means of using at least one of the following culture media: a neural induction complete culture medium, an N2 culture medium, a B27 culture medium and an OPC maturation culture medium. More preferably, the induction of oligodendrocytes by an OPC maturation culture medium with puerarin increases the number of oligodendrocytes by 30% compared with a culture medium without puerarin.
    Type: Application
    Filed: November 28, 2023
    Publication date: March 21, 2024
    Applicant: ALLIFE MEDICINE (ZHUHAI) LIMITED
    Inventors: Lida WU, Yuchun GU
  • Patent number: 11203663
    Abstract: Provided a method for separating PHA and PHA prepared therefrom. The method comprises the following steps: subjecting a PHA fermentation broth to solid-liquid separation to obtain a thallus precipitate; breaking cell walls of the thallus precipitate, and subjecting obtained wall-broken products to a plate and frame filtration to obtain PHA; a filter cloth for the plate and frame filtration is pre-coated with a PHA layer. The method adopts a plate and frame separation to replace the traditional centrifugal separation to prepare PHA, and the PHA layer is pre-coated on the filter cloth for the plate and frame filtration, thereby overcome the defects in the prior art such as high cost and operational difficulty caused by adopting multiple centrifugal separations; in addition, the method of the present disclosure also exhibits the advantages of high recovery rate of PHA and high purity of the prepared PHA product.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: December 21, 2021
    Assignees: COFCO (jilin) Bio-Chemical Technology CO., Ltd, Nutrition & Health Research Institute, COFCO Corporation, COFCO BIOTECHNOLOGY CO., LTD.
    Inventors: Yi Tong, Yi Li, Fang Tian, Kejia Xu, Yuanheng Guo, Bo Chen, Tai An, Dayong Li, Haijun Liu, Lida Wu
  • Publication number: 20210379548
    Abstract: The present invention relates to the field of high polymer material manufacturing, and discloses an air-isolated continuous feeding system for synthesizing polylactic acid from lactide and a feeding method thereof. The continuous feeding system comprises a raw material bag/box and a raw material collector for collecting and outputting lactide, the raw material bag/box is connected with a shielding gas input pipeline, a discharge pipe is movably inserted into the raw material bag/box, a cyclone separator is connected downstream of the discharge pipe, and a solid substance outlet of the cyclone separator is connected with the raw material collector. According to the invention, deterioration of the lactide raw material incurred by moisture absorption and oxidation is avoided, and the reaction conversion ratio and final product purity are improved. The continuous feeding system is easy to operate, can save manpower and material resources, and is applicable to industrial application.
    Type: Application
    Filed: December 29, 2020
    Publication date: December 9, 2021
    Applicants: Nutrition & Health Research Institute, COFCO Corporation, COFCO (jilin) Bio-Chemical Technology CO., Ltd, Jilin COFCO Biomaterial Co.,Ltd, COFCO Biotechnology Co., Ltd
    Inventors: Yi TONG, Yi LI, Fang TIAN, Bo CHEN, Tai AN, Lida WU
  • Patent number: 11192079
    Abstract: The present invention relates to the field of high polymer material manufacturing, and discloses an air-isolated continuous feeding system for synthesizing polylactic acid from lactide and a feeding method thereof. The continuous feeding system comprises a raw material bag/box and a raw material collector for collecting and outputting lactide, the raw material bag/box is connected with a shielding gas input pipeline, a discharge pipe is movably inserted into the raw material bag/box, a cyclone separator is connected downstream of the discharge pipe, and a solid substance outlet of the cyclone separator is connected with the raw material collector. According to the invention, deterioration of the lactide raw material incurred by moisture absorption and oxidation is avoided, and the reaction conversion ratio and final product purity are improved. The continuous feeding system is easy to operate, can save manpower and material resources, and is applicable to industrial application.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: December 7, 2021
    Assignees: Nutrition & Health Research Institute, COFCO Corporation, COFCO (jilin) Bio-Chemical Technology CO., Ltd, Jilin COFCO Biomaterial Co., Ltd, COFCO Biotechnology Co., Ltd.
    Inventors: Yi Tong, Yi Li, Fang Tian, Bo Chen, Tai An, Lida Wu
  • Publication number: 20210340316
    Abstract: Provided a method for separating PHA and PHA prepared therefrom. The method comprises the following steps: subjecting a PHA fermentation broth to solid-liquid separation to obtain a thallus precipitate; breaking cell walls of the thallus precipitate, and subjecting obtained wall-broken products to a plate and frame filtration to obtain PHA; a filter cloth for the plate and frame filtration is pre-coated with a PHA layer. The method adopts a plate and frame separation to replace the traditional centrifugal separation to prepare PHA, and the PHA layer is pre-coated on the filter cloth for the plate and frame filtration, thereby overcome the defects in the prior art such as high cost and operational difficulty caused by adopting multiple centrifugal separations; in addition, the method of the present disclosure also exhibits the advantages of high recovery rate of PHA and high purity of the prepared PHA product.
    Type: Application
    Filed: December 30, 2020
    Publication date: November 4, 2021
    Applicants: COFCO (jilin) Bio-Chemical Technology CO., Ltd, Nutrition & Health Research Institute, COFCO Corporation, COFCO BIOTECHNOLOGY CO., LTD.
    Inventors: Yi Tong, Yi Li, Fang Tian, Kejia Xu, Yuanheng Guo, Bo Chen, Tai An, Dayong Li, Haijun Liu, Lida Wu